Nvidia-Backed Iambic Files IPO and Signs AbbVie
Iambic Therapeutics filed for a US IPO on 21 September and announced a multi-year drug-discovery collaboration with AbbVie the same day. Nvidia is among the AI-driven biotech company’s disclosed investors. The proposed listing could provide a public market valuation for Nvidia’s stake if the offering is priced and completed. AbbVie’s agreement gives Iambic a large pharmaceutical research customer for its platform, a different form of validation from an investor funding round. The companies will pursue small-molecule therapies in immunology, neuroscience and oncology. Nvidia’s immediate economic link is its investment in Iambic, while the pharmaceutical agreement gives that portfolio company a substantial new research relationship.
AbbVie said Iambic will receive an upfront payment and could earn success-based milestones and tiered royalties on products that eventually reach sales. The arrangement ties part of Iambic’s economics to research progress and eventual product sales. Their collaboration will use Iambic’s Enchant v3, a multimodal model that combines data from several stages of drug discovery and was trained on more than 6,000 molecular properties, according to AbbVie. The research aims to test many candidate-design hypotheses in parallel while AbbVie contributes therapeutic expertise. An agreement to begin that work is valuable for Iambic’s business development, yet medicine discovery still requires experimental validation, clinical trials and regulatory decisions before royalties become possible.
Iambic said in its IPO filing that it had raised about $461.8 million since inception. Its lead candidate, IAM1363, is in an early clinical study for solid tumors; other programs are at different development stages. The offering could fund a costly pipeline and put a public price on Iambic’s equity. That would give Nvidia’s existing stake a market reference, while its realized return would depend on ownership, liquidity and the share price after listing. Iambic’s partnership strategy offers another potential source of cash and research progress, although AbbVie’s payments accrue to Iambic rather than directly to Nvidia.
The investment also gives Nvidia exposure to an industry testing whether accelerated computing and AI can improve scientific workflows. Iambic’s platform uses AI in molecular design, a field where model development and large biological datasets may generate demand for computing over time. The AbbVie work advances an application company in Nvidia’s portfolio and can expand the case for AI-assisted molecular design across pharmaceutical research. A public valuation could make the financial side of Nvidia’s existing stake more visible, while clinical and partnership results will shape that valuation well beyond the IPO. Nvidia’s economic role here differs from its direct data center transactions: it owns a position in a potential application winner rather than controlling the drug-development outcome.
Analysis
Iambic offers Nvidia an investment return path linked to AI drug discovery, and the AbbVie collaboration improves the portfolio company’s case for having a useful platform. A priced IPO would reveal a market valuation for that exposure, but Nvidia’s ownership and future liquidity determine the actual financial effect. The agreement with AbbVie is more meaningful than a laboratory demonstration because it brings a paying pharmaceutical partner into the workflow; clinical success remains a much longer-term source of value. This is a strategic and investment story for Nvidia, with a smaller and less direct sales route than its infrastructure deals.